Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers (MetLung)

Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blot of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the potential presence of intracellular fragments, and their phosphorylation status.

Study Overview

• Status: Completed
• Conditions: Non Small Cell Lung Cancer
• Intervention / Treatment: Other: Met analysis on tissue and blood

Detailed Description

• Patient information and collection of signed inform consent
• Blood sample collection before bronchoscopy or before surgery, at the same time as a usual blood assessment.
• Prospective collection of bronchial biopsies of patients with metastatic non small cell lung cancer, during a bronchoscopy at the Oscar Lambret Center (Dr Dansin)
• Prospective collection of resected specimens of patients with localized non small cell lung cancer, who were operated at the thoracic surgery unit of the University hospital (Pr Porte)
• Transportation of the samples to the pathology laboratories (Dr Robin, Pr Copin)
• Selection of blocks of interest and preparation of tumor samples
• Clinical data collection : date of biopsy or surgery, disease-free survival, overall survival, tumor characteristics, EGFR status, ALK, BRAF, HER2
• Transportation of tumor blocks and blood samples to the Institute of Biology of Lille for analyses: Western blot, immunohistochemistry and ELISA test)
• Return to storage of the tumor samples at the Oscar Lambret Center and at the University hospital of Lille

• Study Type: Interventional
• Enrollment (Actual): 56
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Lille, France, 59 037
    • Centre Hospitalier Regional Et Universitaire
  • Lille, France, 59020
    • Oscar Lambret Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with non small cell lung cancer (NSCLC)
• Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage)
• Treatment naive patient for metastatic NSCLC
• Patients with or without neoadjuvant therapy for localized NSCLC
• Male or female patients aged ≥ 18 years
• Patient registered with the social security system
• Having signed a written Informed Consent

Exclusion Criteria:

• Malignant tumors which are not carcinoma
• Small-cell malignant tumors
• Secondary bronchial lesions
• Revision surgery
• Pregnant or breastfeeding women
• Patient under guardianship or tutorship
• Previous cancer

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Met analysis; Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test	Other: Met analysis on tissue and blood; 10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Expression and localization of Met C-terminal active fragments in NSCLC	Western Blot and immunohistochemistry	baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the activation of Met receptor	Activation of Met receptor by immunochemical analysis (Western Blot)	baseline
Correlation between expression of Met receptor fragments with clinical characteristics and/or prognosis factors as sex, TNM, EGFR status, histology, smoking status, survival	Relationships between Met receptor expression and sex, TNM, EGFR status, histology, smoking status, survival	baseline
Expression in plasma of N-terminal Met fragments	ELISA test	baseline

Collaborators and Investigators

• Sponsor: Centre Oscar Lambret
• Investigators: Study Director: David TULASNE, PhD, Institute of Biology of Lille; Study Director: Eric DANSIN, MD, Centre Oscar Lambret

Study record dates

Study Major Dates

• Study Start (Actual): August 27, 2012
• Primary Completion (Actual): July 1, 2015
• Study Completion (Actual): July 1, 2016

Study Registration Dates

• First Submitted: July 17, 2012
• First Submitted That Met QC Criteria: July 23, 2012
• First Posted (Estimated): July 24, 2012

Study Record Updates

• Last Update Posted (Actual): March 13, 2026
• Last Update Submitted That Met QC Criteria: March 12, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Met fragments expression
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Investigative Techniques; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Blood Specimen Collection
• Other Study ID Numbers: MetLung - 1204; 2012-A00468-35 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO